Company news

Corcept Therapeutics Incorporated news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update

October 29, 2024

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

July 21, 2024

Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions

June 23, 2024

Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)

June 2, 2024

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)

May 27, 2024

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

April 30, 2024

Corcept Completes Enrollment in Phase 4 CATALYST Trial

April 28, 2024

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

April 23, 2024

Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome

April 21, 2024

Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

April 14, 2024

Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

April 7, 2024

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

March 31, 2024

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

February 14, 2024

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

February 14, 2024

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

February 7, 2024

Corcept Appoints Roberto Vieira as President, Oncology

January 28, 2024

Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program

January 7, 2024

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

October 31, 2023

Corcept Appoints Monica Tellado as President, Emerging Markets

October 31, 2023

Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)

October 25, 2023

Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)

July 16, 2023

Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer

June 26, 2023

Corcept Therapeutics Announces Final Results of Tender Offer

April 4, 2023

Corcept Therapeutics Announces Preliminary Results of Tender Offer

April 2, 2023

Corcept Therapeutics Initiates CATALYST Clinical Trial

March 27, 2023

Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock

March 5, 2023

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update

February 27, 2023

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call

February 13, 2023

Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation

February 12, 2023

Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals

December 7, 2022

Corcept Therapeutics Provides Miricorilant Clinical Development Update

December 7, 2022

Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)

October 10, 2022

Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer

June 28, 2022

Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer

June 5, 2022

Corcept Therapeutics Announces First Quarter Financial Results And Provides Corporate Update

May 4, 2022

Corcept Therapeutics Announces Appointment of Three Senior Leaders

April 6, 2022

Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain

April 3, 2022

Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer

March 29, 2022

Corcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31, 2022

February 28, 2022

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate Update

February 14, 2022

Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call

February 7, 2022

Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer

December 19, 2021

Corcept Therapeutics Announces Preliminary Results of Previously Announced Tender Offer

December 15, 2021

Corcept Therapeutics Announces Waiver of Condition to its Tender Offer for Common Shares

December 14, 2021

Corcept Therapeutics Announces Extension of Previously Announced Tender Offer

December 7, 2021

Corcept Therapeutics to Present at Upcoming Investor Conferences

November 9, 2021

Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 10 Million Shares of its Common Stock

November 7, 2021

Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update

November 2, 2021

Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer

September 16, 2021

Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021

September 8, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 10 decks. Every deck is listed under its year.